HC Wainwright Rates Akebia Therapeutics (AKBA) buy
HC Wainwright maintains a buy rating for AKBA with a $6 price target, a 393.83% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Akebia Therapeutics, Inc. ($AKBA) "buy" with a $6 price target on July 1, 2026.
Since the rating, $AKBA is up 17.4% after 1 week, up 9.1% after 1 month and down 44.6% to date (from the $1.21 close on Jul 1, 2026).
AKBA
Akebia Therapeutics, Inc.
Key Points
- HC Wainwright reiterated its buy rating on AKBA, setting a $6 price target on July 1, 2026.
- HC Wainwright's $6 price target implies 393.83% upside from Akebia Therapeutics, Inc.'s ($AKBA) current $1.22 share price.
- Shares of AKBA traded at $1.15 on Wednesday, reflecting recent analyst activity.
- Insider purchases and institutional moves like Vanguard's new position highlight interest in AKBA.
Get $AKBA trade alerts by text
We text you when insiders, Congress or big funds trade $AKBA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Akebia Therapeutics, Inc. alert may contain errors. Disclosures
HC Wainwright has reiterated its buy rating on AKBA, setting a price target of $6. This reaffirmation came on July 1, 2026, as analyst Matthew Caufield expressed continued confidence in the stock's potential.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in AKBA
BlackRock, Inc. trimmed its holdings in AKBA by 625,156 shares, ending with 18,693,296 shares valued at about $25.98 million, a 3.2% decrease. State Street Corp reduced its position by 2,073,555 shares, holding 11,614,006 shares worth approximately $16.14 million, marking a 15.1% decrease. Vanguard Capital Management LLC opened a new position with 11,166,710 shares valued at roughly $15.52 million. Meanwhile, Geode Capital Management, LLC increased its stake by 175,075 shares to a total of 6,452,252 shares, valued at about $8.97 million, a 2.8% increase. Goldman Sachs Group Inc cut its position by 1,103,610 shares, holding 3,602,827 shares worth $5.00 million, a 23.4% decrease.
Akebia Therapeutics, Inc. Stock Up 32.7%
On Wednesday, shares of AKBA traded at $1.15. Despite recent fluctuations, the stock has drawn attention from both analysts and institutional investors. Recent insider buying also suggests a potential positive outlook.
$AKBA price target
Akebia Therapeutics, Inc. daily closes and this analyst's $6 target. Not advice.
Insider Buying and Selling at Akebia Therapeutics, Inc.
On June 17, 2026, several insiders made significant purchases. Michael Rogers, Myles Wolf, and Cynthia Smith each bought 53,600 shares, while Leanne Zumwalt and Rogers bought an additional 35,700 shares each. These transactions were not part of a planned trading program, indicating a personal vote of confidence in the company's future.
Analysts Set New Price Targets
On July 1, 2026, HC Wainwright & Co. reiterated its buy rating for AKBA, setting a price target of $6. Earlier in the year, BTIG and Piper Sandler maintained their buy ratings with targets of $4. The consensus among analysts remains positive, with several maintaining buy ratings and price targets supporting potential growth.
Bottom Line
HC Wainwright's reiterated buy rating and $6 price target for AKBA reflect ongoing confidence in the company's prospects. Institutional and insider activities further underscore interest in the stock, although it's important to remember that these are backward-looking indicators. Investors should consider these factors along with broader market conditions when evaluating AKBA.
Related Filing Alerts
Source: HC Wainwright's rating change on $AKBA (Jul 1, 2026). Written by software, not financial advice. How we make alerts